We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vernalis | LSE:VER | London | Ordinary Share | GB00B3Y5L754 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.17 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVER
RNS Number : 3955M
Vernalis PLC
12 October 2016
12 October 2016
LSE: VER
Vernalis plc
Director/PDMR Dealing
Vernalis plc (LSE: VER) ("the Company") announces that Ian Garland, Chief Executive Officer of the Company was today allotted 91,310 ordinary shares of 1 pence each ("Ordinary Shares") following his exercise of options under the Company's 2007 Bonus Long-Term Incentive Plan ("LTIP").
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1. Details of PDMR / person closely associated with them ("PCA") --- --------------------------------------------------------------------------- a) Name Ian Garland --- ------------------------------ ------------------------------------------- 2. Reason for the notification --- --------------------------------------------------------------------------- a) Position / status Chief Executive Officer --- ------------------------------ ------------------------------------------- b) Initial notification Initial notification / amendment --- ------------------------------ ------------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- --------------------------------------------------------------------------- a) Name Vernalis plc --- ------------------------------ ------------------------------------------- b) Legal Entity n/a Identifier --- ------------------------------ ------------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- --------------------------------------------------------------------------- a) Description of Ordinary shares of 1 pence each ("Ordinary the financial Shares") instrument GB00B3Y5L754 --- ------------------------------ ------------------------------------------- b) Nature of the Exercise and Allotment of Ordinary transaction Shares under the Company's LTIP --- ------------------------------ ------------------------------------------- c) Price(s) and Price(s) Volume(s) volume(s) --------- ----------------------- 1 pence 91,310 Ordinary Shares --------- ----------------------- --- ------------------------------ ------------------------------------------- d) Aggregated information * Aggregated volume N/A - single transaction * Aggregated price * Aggregated total --- ------------------------------ ------------------------------------------- e) Date of the transaction 12 October 2016 (UK) --- ------------------------------ ------------------------------------------- f) Place of the Outside a trading venue transaction --- ------------------------------ -------------------------------------------
-- ends -
Enquiries:
Vernalis plc: +44 (0) 118 938 0015 Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer Canaccord Genuity Limited (Nominated Adviser and Joint Broker): +44 (0) 20 7523 8000 Dr Julian Feneley Rupert Winckler Henry Fitzgerald-O'Connor Emma Gabriel Shore Capital (Joint Broker): +44 (0)20 7408 4090 Bidhi Bhoma Toby Gibbs FTI Consulting: +44 (0) 20 3727 1000 Ben Atwell Simon Conway
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra(R) XR, targeting the US prescription cough-cold market; Moxatag(R) , a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and Tris.
For further information about Vernalis, please visit www.vernalis.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGGGQAUUPQGAP
(END) Dow Jones Newswires
October 12, 2016 11:57 ET (15:57 GMT)
1 Year Vernalis Chart |
1 Month Vernalis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions